image credit: Adobe Stock

Regeneron bets on ‘Treg’ cell therapy with Sonoma deal

Regeneron became one of biotech’s most valuable companies through its success making antibody drugs. Its flagship technology, a way of testing potential medicines on genetically modified mice, has helped it unearth antibody treatments for eye diseases, autoimmune conditions, rare disorders and cancer.

More recently, Regeneron has shown interest in newer drugmaking methods, too. Alliances with Intellia Therapeutics and Alnylam Pharmaceuticals gave it rights to experimental gene editing and RNA interference medicines, respectively. A partnership with 2seventy bio has proved cell therapy — genetically altering human cells to fight disease — is on its radar as well.

Read More on Biopharma Dive